ADB-FUBINACA

195.007,000.00

ADB-FUBINACA

ADB-FUBINACA has a high potential for abuse due to its quick onset and long duration of action, high potency, and a high threshold. This high potency and high threshold lead to a high risk of overdose for the individual who is dependent on synthetic cannabis. ADB-FUBINACA is also listed as an experimental drug in the category of “drugs with no currently accepted medical use in treatment in the United States” in the United States’ most recent United States Food and Drug Administration (FDA) product label. Adb-Fubinaca is also known as 17-ANB, 17-acetyl-5-fluoro-ADB, AB-FUBINACA, and 18-Io-FUBINACA. ADB-FUBINACA is being developed by Pharmaleads and has been recently approved by the Food and Drug Administration of the United States as a Schedule 1 controlled substance in April 2018

Clear